Feb 1 (Reuters) - SENSORION SA ALSEN.PA :
* SENSORION IS NOW FINANCED THROUGH A NUMBER OF KEY VALUE
INFLECTION POINTS WITH A CASH RUNWAY THAT EXTENDS UNTIL H2 2022
* STUDY IN SUDDEN SENSORINEURAL HEARING LOSS: GROUP EXPECTS
RESULTS FROM PHASE II STUDY IN Q4 2021
* WE ALSO ANTICIPATE INITIATING A PROOF-OF-CONCEPT CLINICAL
STUDY
OF SENS-401 IN CISPLATIN INDUCED OTOTOXICITY (CIO) IN H2 2021
* GROUP WILL ALSO REMAIN ACTIVE IN PROGRESSING ITS
PARTNERSHIP
PROGRAMS
* SENSORION AND COCHLEAR ARE ASSESSING POSSIBILITY OF
CONDUCTING
CLINICAL STUDIES FOR SENS-401 IN COCHLEAR IMPLANT PATIENTS
Source text for Eikon: ID:nNDL1cyZSj
Further company coverage: ALSEN.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; 48 58 7696600;))